598 related articles for article (PubMed ID: 28699646)
21. A pharmacogenetics approach to pain management.
Yoshida K; Nishizawa D; Ide S; Ichinohe T; Fukuda KI; Ikeda K
Neuropsychopharmacol Rep; 2018 Mar; 38(1):2-8. PubMed ID: 30106264
[TBL] [Abstract][Full Text] [Related]
22. Pain polymorphisms and opioids: An evidence based review.
Vieira CMP; Fragoso RM; Pereira D; Medeiros R
Mol Med Rep; 2019 Mar; 19(3):1423-1434. PubMed ID: 30592275
[TBL] [Abstract][Full Text] [Related]
23. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
24. Pharmacogenetics of OPRM1.
Crist RC; Berrettini WH
Pharmacol Biochem Behav; 2014 Aug; 123():25-33. PubMed ID: 24201053
[TBL] [Abstract][Full Text] [Related]
25. [Interindividual variation of pharmacokinetic disposition of and clinical responses to opioid analgesics in cancer pain patients].
Naito T; Kawakami J
Yakugaku Zasshi; 2015; 135(5):709-15. PubMed ID: 25948306
[TBL] [Abstract][Full Text] [Related]
26. The value of CYP2D6 and OPRM1 pharmacogenetic testing for opioid therapy.
Reynolds KK; Ramey-Hartung B; Jortani SA
Clin Lab Med; 2008 Dec; 28(4):581-98. PubMed ID: 19059064
[TBL] [Abstract][Full Text] [Related]
27. Pharmacogenetics-guided analgesics in major abdominal surgery: Further benefits within an enhanced recovery protocol.
Senagore AJ; Champagne BJ; Dosokey E; Brady J; Steele SR; Reynolds HL; Stein SL; Delaney CP
Am J Surg; 2017 Mar; 213(3):467-472. PubMed ID: 27955884
[TBL] [Abstract][Full Text] [Related]
28. Pharmacogenetic Guided Opioid Therapy Improves Chronic Pain Outcomes and Comorbid Mental Health: A Randomized, Double-Blind, Controlled Study.
Agulló L; Aguado I; Muriel J; Margarit C; Gómez A; Escorial M; Sánchez A; Fernández A; Peiró AM
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445931
[TBL] [Abstract][Full Text] [Related]
29. Clinical implications of opioid pharmacogenetics.
Argoff CE
Clin J Pain; 2010 Jan; 26 Suppl 10():S16-20. PubMed ID: 20026961
[TBL] [Abstract][Full Text] [Related]
30. Analgesia and Opioids: A Pharmacogenetics Shortlist for Implementation in Clinical Practice.
Matic M; de Wildt SN; Tibboel D; van Schaik RHN
Clin Chem; 2017 Jul; 63(7):1204-1213. PubMed ID: 28637770
[TBL] [Abstract][Full Text] [Related]
31. Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management.
Jannetto PJ; Bratanow NC
Pharmacogenomics; 2009 Jul; 10(7):1157-67. PubMed ID: 19604091
[TBL] [Abstract][Full Text] [Related]
32. Analysis Approaches to Identify Pharmacogenetic Associations With Pharmacodynamics.
Hertz DL; Ramsey LB; Gopalakrishnan M; Leeder JS; Van Driest SL
Clin Pharmacol Ther; 2021 Sep; 110(3):589-594. PubMed ID: 34043820
[TBL] [Abstract][Full Text] [Related]
33. The pharmacogenetics of codeine pain relief in the postpartum period.
Baber M; Chaudhry S; Kelly L; Ross C; Carleton B; Berger H; Koren G
Pharmacogenomics J; 2015 Oct; 15(5):430-5. PubMed ID: 25752520
[TBL] [Abstract][Full Text] [Related]
34. Clinical application of pharmacogenetics in pain management.
Smith DM; Weitzel KW; Cavallari LH; Elsey AR; Schmidt SO
Per Med; 2018 Mar; 15(2):117-126. PubMed ID: 29714124
[TBL] [Abstract][Full Text] [Related]
35. Pharmacogenetics and prediction of adverse events in prescription opioid use disorder patients.
Muriel J; Margarit C; Barrachina J; Ballester P; Flor A; Morales D; Horga JF; Fernández E; Peiró AM
Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):439-448. PubMed ID: 30549211
[TBL] [Abstract][Full Text] [Related]
36. [Genetic polymorphisms and human sensitivity to pain and opioids].
Nishizawa D; Nagashima M; Satoh Y; Tagami M; Ikeda K
Masui; 2009 Sep; 58(9):1093-101. PubMed ID: 19764431
[TBL] [Abstract][Full Text] [Related]
37. Influence of Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 (CYP2D6) polymorphisms on pain sensitivity and clinical response to weak opioid analgesics.
Zahari Z; Ismail R
Drug Metab Pharmacokinet; 2014; 29(1):29-43. PubMed ID: 23759977
[TBL] [Abstract][Full Text] [Related]
38. Association Between Human Pain-Related Genotypes and Variability in Opioid Analgesia: An Updated Review.
Nielsen LM; Olesen AE; Branford R; Christrup LL; Sato H; Drewes AM
Pain Pract; 2015 Jul; 15(6):580-94. PubMed ID: 25201705
[TBL] [Abstract][Full Text] [Related]
39. The role of hydromorphone and OPRM1 in postoperative pain relief with hydrocodone.
Boswell MV; Stauble ME; Loyd GE; Langman L; Ramey-Hartung B; Baumgartner RN; Tucker WW; Jortani SA
Pain Physician; 2013; 16(3):E227-35. PubMed ID: 23703421
[TBL] [Abstract][Full Text] [Related]
40. CYP2D6 phenotypes and opioid metabolism: the path to personalized analgesia.
Ballester P; Muriel J; Peiró AM
Expert Opin Drug Metab Toxicol; 2022 Apr; 18(4):261-275. PubMed ID: 35649041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
